Mazdutide
Also known as: LY3305677 · IBI362
A dual GLP-1/glucagon agonist developed in China, achieving 15–18% weight loss that rivals tirzepatide in Phase 3 trials.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~6–7 days
6–9 mg weekly
Subcutaneous injection
Mechanism of Action
Combines GLP-1 appetite suppression with glucagon-mediated thermogenic fat burning for synergistic weight reduction.
Key Research Areas
Frequently Asked Questions
What is Mazdutide?▾
How does Mazdutide work?▾
What is the recommended dosage for Mazdutide?▾
What is the half-life of Mazdutide?▾
Is Mazdutide FDA approved?▾
Ready to get started with Mazdutide?
Order from our COA-verified partner — free US shipping, pharmaceutical-grade quality.
Research Disclaimer
The information provided about Mazdutide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.